* Age (continuous), gender, hypertension, diabetes mellitus, dyslipidemia, family history of coronary artery disease, current smoking, prior stroke, chronic congestive heart failure, prior myocardial infarction, prior percutaneous coronary intervention or coronary artery bypass grafting, chronic renal failure, diagnosis (ST-elevation myocardial infarction vs. non ST-elevation myocardial infarction) on arrival and P2Y12 inhibitor treatment. This evidence concerns the gene P2RY12 and chronic kidney disease.